drugset / Trial / NCT05718492

A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents

NCT05718492

Recruiting 100 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

Immune checkpoint inhibitors (ICIs) plus antiangiogenic agents can achieve better efficacy than sorafenib in the treatment of hepatocellular carcinoma (HCC) within a certain period of time, but more than half of the patients are still insensitive to the treatment. There is no evidence-based basis for second-line treatment after the progression of the disease.In view of the effectiveness of Hepatic arterial infusion (HAIC) in the first-line treatment of HCC in the Chinese population, this study intends to launch a prospective intervention study to explore the efficacy and safety of HAIC treatment in patients with advanced HCC after the failure of ICIs and antiangiogenic agents combination therapy, and to provide high-level evidence for optimizing the second-line treatment of advanced HCC in the future.

Timeline

Start
2022-10-18
Primary completion
2025-10-18
Completion
2026-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule 130 mg/m2 Other
Subject fluorouracil Small molecule 2400 mg/m2 Other
Background Leucovorin Small molecule 200 mg/m2 Other